Share This Author
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
- E. Papaemmanuil, M. Gerstung, P. Campbell
- Medicine, BiologyNew England Journal of Medicine
- 8 June 2016
The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification.
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, MLL, and MLL are associated with the outcome of treatment for patients with cytogenetically normal AML.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event‐free survival among patients with AML and a FLT3 mutation.
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
NPM1 mutations in the absence of FLT3 ITD define a distinct molecular and prognostic subclass of young-adult AML patients with normal cytogenetics, and is associated with specific clinical, phenotypical, and genetic features.
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3…
IDH1 and IDH2 mutations are recurring genetic changes in AML that constitute a poor prognostic factor in CN-AML with mutated NPM1 without FLT3-ITD, which allows refined risk stratification of this AML subset.
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.
The use of gene-expression profiling improves the molecular classification of adult AML and identifies new molecular subtypes of AML, including two prognostically relevant subgroups in AML with a normal karyotype.
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
In multivariate analysis, p53 gene deletion was the strongest prognostic factor for survival and predicts for non-response to therapy with purine analogs and for poor survival in chronic B-cell leukemias.
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
To assess the prognostic relevance of activating mutations of the FLT3 gene in homogeneously treated adults 16 to 60 years of age with acute myeloid leukemia (AML) and normal cytogenetics,…
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.
In more intensively treated younger adults, treatment-related toxicity had a major negative impact on outcome, possibly reflecting cumulative toxicity of cancer treatment.